Results 41 to 50 of about 24,911 (203)

The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease. [PDF]

, 2020
Sickle cell disease (SCD) is an extremely heterogeneous disease that has been associated with global morbidity and early mortality. More effective and inexpensive therapies are needed.
Ballas, Samir K
core   +1 more source

Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. [PDF]

, 2017
Natural killer (NK) cells are innate cytotoxic lymphoid cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance.
Borrelli, Cristiana, Cippitelli, Marco, Fionda, Cinzia, Santoni, Angela, Soriani, Alessandra, Zingoni, Alessandra   +5 more
core   +1 more source

Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition

Advanced Science, EarlyView.
The authors engineer colorectal cancer cells with reduced redundancy of UHRF1 and DNMT1, key DNA methylation maintenance factors, lowering the maintenance threshold and sensitizing cells to inhibition. They develop reporter assays driven by endogenous tumor‐suppressor gene promoters with enhanced sensitivity and dynamic range to demethylating drugs ...
Cuicui Xia, Ying Cui, Jiongliang Wang, Wenjing Bai, Danyang Wang, Yao Chen, Huahui Guo, Liangyi Zong, Bing Qin, Xintong Cai, Jie Wang, Jing Huang, Scott B. Rothbart, Zufeng Guo, Stephen B. Baylin, Xiangqian Kong   +15 more
wiley   +1 more source

Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation

Cancer Cell International, 2007
Background Methylation-mediated silencing of genes is one epigenetic mechanism implicated in cancer. Studies regarding the role of modulation of gene expression utilizing inhibitors of DNA methylation, such as decitabine, in osteosarcoma (OS) have been ...
Xue Hui, Cutz Jean-Claude, Prasad Mona, Bayani Jane, Hughes Simon, Somers Gino R, Al-Romaih Khaldoun, Zielenska Maria, Wang Yuzhuo, Squire Jeremy A   +9 more
doaj   +1 more source

Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis

Open Life Sciences, 2020
Previous research has revealed the involvement of microRNA-212-5p (miR-212-5p) and cyclin T2 (CCNT2) in acute myeloid leukemia (AML). However, whether the miR-212-5p/CCNT2 axis is required for the function of decitabine in AML has not been well ...
Xing Lina, Ren Jinhai, Guo Xiaonan, Qiao Shukai, Tian Tian   +4 more
doaj   +1 more source

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

RETRACTED ARTICLE: The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine

Clinical Epigenetics
Background Decitabine has been widely used to treat acute myeloid leukemia (AML); however as AML is a heterogeneous disease, not all patients benefit from decitabine. This study aimed to identify markers for predicting the response to decitabine. Methods
Yi Li, Xia Mao, Mengyuan Li, Li Li, Xiwen Tong, Lifang Huang   +5 more
doaj   +1 more source

Gender effects on cytidine analogue metabolism and myelodysplastic syndrome treatment outcomes [PDF]

, 2012
In vivo, half-lives of cytidine analogues such as 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), are determined largely by cytidine deaminase (CDA), an enzyme that rapidly metabolizes these drugs into inactive uridine ...
Ania Jankowska, Jaroslaw Maciejewski, Joseph Covey, Kenneth Chan, Kory Engelke, Mikkael Sekeres, Pramod Terse, Quteba Ebrahem, Ramon Tiu, Reda Mahfouz, Tomas Radivoyevitch, Yogen Saunthararajah, Yonghua Ling, Zhenbo Hu   +13 more
core   +1 more source

The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine [PDF]

, 2016
Decitabine (5-aza-2acute;-deoxycytidine, aza-dCyd) is an anticancer drug used clinically for the treatment of myelodysplastic syndromes and acute myeloid leukemia that can act as a DNA-demethylating or genotoxic agent in a dose-dependent manner.
Horváth, András, Perez-Moreno, G., Requena, C. E., Ruiz-Perez, L. M., Vértessy, Beáta (Grolmuszné)   +4 more
core   +1 more source